Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026

Pasithea Therapeutics Corp. (KTTA) — Rebecca M. Brown, MD, and Kavita Sarin, MD, PhD, will join management to discuss unmet needs and the treatment landscape for NF1-associated cutaneous and plexiform neurofibromasMIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1) associated

Source: GlobeNewswire — read the full announcement there.

See our Pasithea Therapeutics company profile for background, links, and more Pasithea Therapeutics news.